Ablatotech Biotechnology Healing Systems

At Ablatotech, we are rewriting the rules of medicine by harnessing the body’s natural potential to heal and thrive. Born out of the visionary mind of Dr. George Ekema—an award-winning drug discovery scientist and accomplished patent lawyer—Ablatotech stands at the forefront of biotherapeutic innovation. With a profound commitment to transforming lives, we are dedicated to developing groundbreaking technologies that not only trick the body into healing itself but also amplify its innate ability to recover and regenerate.

​

Our flagship innovation, Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), is set to redefine the healthcare industry. DAPYTAP enables us to create drugs that are not only safer and more effective than current treatments but also incredibly affordable—reaching even the world’s most underserved populations. Imagine a future where revolutionary therapies are within reach for everyone, from the wealthiest nations to the poorest villages. This is the vision driving Ablatotech forward.

​

Our mission is bold yet clear: to disrupt the healthcare landscape by delivering biotherapeutics that break barriers in accessibility, efficacy, and safety. Through relentless innovation, Ablatotech is poised to lead a paradigm shift, transforming medicine from a system of treatment into one of natural healing and self-repair.

​

For investors seeking to be part of a monumental change in global healthcare, Ablatotech is your opportunity to not only generate impact but to be part of a legacy. Together, we are shaping a world where healing knows no borders, and hope is universal. Welcome to the future of medicine—welcome to Ablatotech.